Daclatasvir (DCV) plus Sofosbuvir (SOF) regimens in chronic Hepatitis C Virus (HCV) infected patients with advanced fibrosis or cirrhosis

被引：0

作者：

Elefsiniotis, Loannis S. ^{[1
]}

Dalekos, George N. ^{[2
,3
]}

Koskinas, John ^{[4
]}

Ioannidou, Panagiota ^{[6
]}

Cholongitas, Evangelos ^{[5
]}

Manolakopoulos, Spilios ^{[4
]}

Goulis, John ^{[5
]}

Vlachogiannakos, John ^{[6
]}

Deutsch, Melani ^{[4
]}

Triantos, Christos K. ^{[7
]}

Kapatais, Andreas ^{[8
]}

Sevastianos, Vassilios A. ^{[9
,10
]}

Schina, Maria J. ^{[9
,10
]}

Karatapanis, Stylianos ^{[11
]}

Ketikoglou, Loannis ^{[4
]}

Manesis, Emanuel K. ^{[4
]}

Papageorgiou, Maria-Vasiliki ^{[6
]}

Sinakos, Emanuel ^{[5
]}

Gatselis, Nikolaos K. ^{[2
,3
]}

Karagiannakis, Dimitrios ^{[6
]}

Tasovasili, Athanasia ^{[1
]}

Koukoufiki, Argyro ^{[5
]}

Voulgaris, Theodoros A. ^{[9
,10
]}

Tsolias, Chrysostomos ^{[7
]}

Akriviadis, Evangelos ^{[5
]}

Papatheodoridis, George V. ^{[6
]}

机构：

[1] Gen & Oncol Hosp Kifisia Agioi Anargyroi, Univ Dept Internal Med, Hepatogastroenterol Unit, Athens, Greece

[2] Univ Thessaly, Sch Med, Dept Med, Larisa, Greece

[3] Univ Thessaly, Sch Med, Res Lab Internal Med, Larisa, Greece

[4] Univ Athens, Hippokratio Gen Hosp Athens, Dept Internal Med 2, Athens, Greece

[5] Aristotle Univ Thessaloniki, Hippokratio Hosp, Med Dept 4, Thessaloniki, Greece

[6] Univ Athens, Laiko Gen Hosp, Dept Gastroenterol, Athens, Greece

[7] Univ Hosp Patras, Dept Gastroenterol, Patras, Greece

[8] Gen Hosp Western Attica, Athens, Greece

[9] Evangelismos Gen Hosp, Dept Internal Med 4, Athens, Greece

[10] Evangelismos Gen Hosp, Liver Outpatient Clin, Athens, Greece

[11] Gen Hosp Rhodes, Rhodes, Greece

来源：

HEPATOLOGY | 2016年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1993

引用

页码：990A / 991A

页数：2

共 50 条

[41] Daclatasvir Plus Sofosbuvir Plus RIbavirin in HCV Genotype 3 Infected Patients with Cirrhosis Child A: A Randomized Trial for 16 or 24 Weeks (NCT #02304159)
Hassanein, Tarek I.
Esshaki, Yasmeen
Hill, Catherine
Pozza, Renee
Higham, Jennifer
Luvisa, B. K.
Hefner, Anna Marie
[J]. HEPATOLOGY, 2016, 64 : 450A - 450A
[42] DACLATASVIR AND SOFOSBUVIR THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS OR POST-LIVER TRANSPLANT HCV RECURRENCE AND ADVANCED FIBROSIS OR CIRRHOSIS: UNITED STATES MULTICENTRETREATMENT PROTOCOL
Brown, R.
Fried, M.
Reddy, R. K.
Pico, C. S.
Khemichian, S.
Darling, J.
Napoli, A. A.
Anduze-Faris, B.
Kwo, P.
[J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S814 - S814
[43] ESTIMATING THE COST-EFFECTIVENESS OF DACLATASVIR REGIMENS FOR PATIENTS WITH ADVANCED CHRONIC HEPATITIS C IN THE UK
McEwan, P.
Webster, S.
Ward, T.
Kalsekar, A.
Yuan, Y.
Brenner, M.
[J]. VALUE IN HEALTH, 2015, 18 (03) : A239 - A239
[44] Response to hepatitis a/B vaccine alone or in combination in patients with chronic hepatitis C virus (HCV) and advanced fibrosis
Sterling, Richard
Kramer, Seth
Hofmann, Charlotte
Smith, Paula
Shiffman, Mitchell
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S118 - S118
[45] REAL - WORLD EFFECTIVENESS AND SAFETY OF SOFOSBUVIR/ELPATASVIR (SOF/ VEL) IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 3b
Nan, Zhiyan
Jiang, Aihua
[J]. HEPATOLOGY, 2023, 78 : S738 - S739
[46] Minimal Impact of Sofosbuvir plus Ribavirin (SOF plus RBV) on Work Productivity of Patients with Chronic Hepatitis C (CH-C)
Younossi, Zobair M.
Stepanova, Maria
Lawitz, Eric
Nelson, David R.
Cooper, Curtis
Nader, Fatema
Afendy, Mariam
Hunt, Sharon L.
[J]. HEPATOLOGY, 2013, 58 : 1279A - 1279A
[47] All-oral 12-week Combination Treatment With Daclatasvir (DCV) and Sofosbuvir (SOF) in Patients Infected with HCV Genotype (GT) 3: ALLY-3 Phase 3 Study
Nelson, David R.
Cooper, James N.
Lalezari, Jacob P.
Lawitz, Eric
Pockros, Paul J.
Gitlin, Norman
Freilich, Bradley
Younes, Ziad
Harlan, William
Ghalib, Reem H.
Oguchi, Godson I.
Thuluvath, Paul J.
Ortiz-Lasanta, Grisell
Rabinovitz, Mordechai
Bernstein, David
Bennett, Michael
Hawkins, Trevor
Ravendhran, Natarajan
Sheikh, Aasim M.
Varunok, Peter
Kowdley, Kris V.
Hennicken, Delphine
McPhee, Fiona
Rana, Khurram
Hughes, Eric A.
[J]. HEPATOLOGY, 2014, 60 (06) : 1268A - 1269A
[48] Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients
Abdelaty, Lamiaa N.
Elnaggar, Ahmed A.
Said, Amira A.
Hussein, Raghda R. S.
[J]. CURRENT DRUG SAFETY, 2020, 15 (01) : 53 - 60
[49] An integrated safety analysis of daclatasvir plus sofosbuvir, with or without ribavirin, in patients with chronic HCV infection
Landis, Charles S.
Nelson, David R.
Sulkowski, Mark S.
Ruane, Peter J.
Mills, Anthony M.
Poordad, Fred
Wyles, David L.
Bhore, Rafia
Ackerman, Peter
Rana, Khurram
Swenson, Eugene S.
Noviello, Stephanie
[J]. HEPATOLOGY, 2015, 62 : 565A - 565A
[50] Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection
Elbaz, Tamer
Abdo, Mahmoud
Omar, Heba
Hassan, Essam A.
Zaghloul, Amr M.
Abdel-Samiee, Mohamed
Moustafa, Ahmed
Qawzae, Abdallah
Gamil, Mostafa
Esmat, Gamal
[J]. JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (02) : 272 - 277

← 1 2 3 4 5 →